Development of New Technologies at Roswell Park to Further Cancer-Based Research and Treatment Through Genome Modification
Development of New Technologies at Roswell Park to Further Cancer-Based Research and Treatment Through Genome Modification
批准号:
10733275
负责人:
Aimee B Stablewski
金额:
$32.49万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-19 至 2028-08-31
关键词:
Animal ModelApplications GrantsAreaBiologyCancer CenterCancer Center Support GrantCell LineCellsCollaborationsComprehensive Cancer CenterConsultConsultationsDedicationsDevelopmentDevelopmental Therapeutics ProgramDoctor of PhilosophyEnsureFundingGene TargetingGeneticGenetically Modified AnimalsGenomeGrantInfrastructureInvestmentsLaboratoriesMalignant NeoplasmsModificationPositioning AttributePrincipal InvestigatorPrivatizationResearchResearch PersonnelResearch Project GrantsResource SharingResourcesScientistSpecialistStressTechnologyTransgenic OrganismsUnited States National Institutes of HealthWagesbasecancer research center directorcareerexperiencegenome editingmemberneoplasm immunotherapynew technologyprogramstooltumor immunology
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
The current application seeks salary support for Aimee Stablewski, PhD who serves as the Director of the
Gene Targeting and Transgenic Shared Resource (GeTT) of Roswell Park Comprehensive Cancer Center
(Roswell Park). This position was created in 1999 to oversee the research applications of the various genome
editing platforms available in the resource and to apply her extensive experience in these areas in
collaborations and consultations with the GeTT investigator user base. With over 25 years of experience in
research applications of the creation of genetically modified animals and cells (23 years at Roswell Park), Dr.
Stablewski throughout her career has collaborated with many investigators at the Cancer Center on NIH
funded projects. The GeTT is an integral part of Roswell Park's Cancer Center Support grant (P30CA016056)
for which the cancer center Director, Dr. Johnson, serves as the Principal Investigator. All three CCSG
programs (Developmental Therapeutics (DT), Tumor Immunology and Immunotherapy (TII) and Cancer Stress
Biology (CSB) equally make up the user base of the GeTT; and numerous NIH-funded researchers in these
programs actively collaborate and consult with Dr. Stablewski. Dr. Stablewski' s contributions to Roswell Parks
research enterprise have been significant and impactful specifically with regards to the NIH-funded research of
the members of the TII program. As of September 2022, there are thirty-nine grant applications that cited use
of the GeTT shared resources. There were twenty-six NIH/ NCI, two DOD, and the remaining applications
include private and public funding sponsors, eleven of whom were TII Program members, fourteen are CSB
members and nine are DT members.
The cancer center has also made significant investments in the GeTT with regards to advancing technology in
genetic modifications. With the changes in the R50 program now making the distinction between Laboratory
(PAR-20-288) and Core (PAR-20-287) based scientists and with the GeTT being an integral part of the
Roswell Park CCSG infrastructure, Dr. Johnson as the PI of the CCSG grant, will now serve as the Unit
Director for the application.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文